The t(6;14)(p21;q32) translocation causes dysregulation of cyclin d3 in multiple myeloma

Ying Qi, Ana Gabrea, Jeffrey Sawyer, John D. Shaughnessy, Bart Barlogie, Peter Leif Bergsagel, W. Michael Kuehl

Research output: Contribution to journalArticle

Abstract

Reciprocal translocations involving the IgH locus (14q32) appear to provide an early transformation event in most multiple myeloma (MM) tumors. These primary translocations are targeted to V/D/J sequences due to errors in VDJ recombination or somatic hypermutation, or to IgH switch regions due to errors in switch recombination. The translocations include a promiscuous array of at least 20 nonrandom chromosomal partners, each including an oncogene that is dysregulated by juxtaposition to potent IgH enhancers. The most frequent partners include: Hql3(cyclin Dl), 4pl6.3 (FGFR3 and MM.SET), and 16q23 (c-maf), which together are present in approximately 50% of MM tumors. Cyclin D3 is expressed at similar levels in 25 MM cell lines, except for one cell line that expresses nearly ten times as much cyclin D3 mRNA and protein as any other cell line. In this MM cell line, FISH analyses confirmed the presence of a t(6; 14)(p21 ;q32) translocation, with close juxtaposition of cyclin D3 and IgH Ea enhancer sequences. The cloned translocation breakpoint junction occurs within a y4 IgH switch region and includes 6p21 sequences that co-localize with cyclin D3 sequences on a BAC clone. In screening a panel of 30 MM tumors, we identified a single tumor with at(6;22)(p21;qll) translocation, with cyclin D3 and CX enhancer sequences juxtaposed on der(6). As a result the IgH and IgX translocations bracket the cyclin D3 gene, similar to results obtained for other genes (c-myc, c-maf) dysregulated by Ig translocations. From conventional cytogenetic and/or SKY analyses of several hundred MM tumors, the t(6;14)(p21;q32) translocation is present in about 2-3% of tumors. Additional FISH analyses of metaphase chromosomes confirm that: 1) cyclin D3 and IgH E<x enhancer sequences are juxtaposed in 4 M VI tumors with t(6;14)(p21;q32); and 2) in at least 3 of these tumors the BAC FISH probe described above identifies both der(14) and der(16), indicating that the breakpoints occur no more than 200 kb centromeric to cyclin D3. We hypothesize that primary [g translocations which dysregulate either cyclin Dl or cyclin D3 promote the transformation of quiescent long-lived plasma cells into proliferating MGUS tumor cells.

Original languageEnglish (US)
JournalBlood
Volume96
Issue number11 PART I
StatePublished - 2000
Externally publishedYes

Fingerprint

Cyclin D3
Multiple Myeloma
Tumors
Neoplasms
Cells
Cell Line
Cyclins
Switches
Genes
V(D)J Recombination
myc Genes
Chromosomes, Human, Pair 1
Metaphase
Chromosomes
Plasma Cells
Oncogenes
Cytogenetics
Genetic Recombination
Screening
Clone Cells

ASJC Scopus subject areas

  • Hematology

Cite this

Qi, Y., Gabrea, A., Sawyer, J., Shaughnessy, J. D., Barlogie, B., Bergsagel, P. L., & Michael Kuehl, W. (2000). The t(6;14)(p21;q32) translocation causes dysregulation of cyclin d3 in multiple myeloma. Blood, 96(11 PART I).

The t(6;14)(p21;q32) translocation causes dysregulation of cyclin d3 in multiple myeloma. / Qi, Ying; Gabrea, Ana; Sawyer, Jeffrey; Shaughnessy, John D.; Barlogie, Bart; Bergsagel, Peter Leif; Michael Kuehl, W.

In: Blood, Vol. 96, No. 11 PART I, 2000.

Research output: Contribution to journalArticle

Qi, Y, Gabrea, A, Sawyer, J, Shaughnessy, JD, Barlogie, B, Bergsagel, PL & Michael Kuehl, W 2000, 'The t(6;14)(p21;q32) translocation causes dysregulation of cyclin d3 in multiple myeloma', Blood, vol. 96, no. 11 PART I.
Qi Y, Gabrea A, Sawyer J, Shaughnessy JD, Barlogie B, Bergsagel PL et al. The t(6;14)(p21;q32) translocation causes dysregulation of cyclin d3 in multiple myeloma. Blood. 2000;96(11 PART I).
Qi, Ying ; Gabrea, Ana ; Sawyer, Jeffrey ; Shaughnessy, John D. ; Barlogie, Bart ; Bergsagel, Peter Leif ; Michael Kuehl, W. / The t(6;14)(p21;q32) translocation causes dysregulation of cyclin d3 in multiple myeloma. In: Blood. 2000 ; Vol. 96, No. 11 PART I.
@article{98b42240e83c48bea0be867344da4b1d,
title = "The t(6;14)(p21;q32) translocation causes dysregulation of cyclin d3 in multiple myeloma",
abstract = "Reciprocal translocations involving the IgH locus (14q32) appear to provide an early transformation event in most multiple myeloma (MM) tumors. These primary translocations are targeted to V/D/J sequences due to errors in VDJ recombination or somatic hypermutation, or to IgH switch regions due to errors in switch recombination. The translocations include a promiscuous array of at least 20 nonrandom chromosomal partners, each including an oncogene that is dysregulated by juxtaposition to potent IgH enhancers. The most frequent partners include: Hql3(cyclin Dl), 4pl6.3 (FGFR3 and MM.SET), and 16q23 (c-maf), which together are present in approximately 50{\%} of MM tumors. Cyclin D3 is expressed at similar levels in 25 MM cell lines, except for one cell line that expresses nearly ten times as much cyclin D3 mRNA and protein as any other cell line. In this MM cell line, FISH analyses confirmed the presence of a t(6; 14)(p21 ;q32) translocation, with close juxtaposition of cyclin D3 and IgH Ea enhancer sequences. The cloned translocation breakpoint junction occurs within a y4 IgH switch region and includes 6p21 sequences that co-localize with cyclin D3 sequences on a BAC clone. In screening a panel of 30 MM tumors, we identified a single tumor with at(6;22)(p21;qll) translocation, with cyclin D3 and CX enhancer sequences juxtaposed on der(6). As a result the IgH and IgX translocations bracket the cyclin D3 gene, similar to results obtained for other genes (c-myc, c-maf) dysregulated by Ig translocations. From conventional cytogenetic and/or SKY analyses of several hundred MM tumors, the t(6;14)(p21;q32) translocation is present in about 2-3{\%} of tumors. Additional FISH analyses of metaphase chromosomes confirm that: 1) cyclin D3 and IgH E",
author = "Ying Qi and Ana Gabrea and Jeffrey Sawyer and Shaughnessy, {John D.} and Bart Barlogie and Bergsagel, {Peter Leif} and {Michael Kuehl}, W.",
year = "2000",
language = "English (US)",
volume = "96",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART I",

}

TY - JOUR

T1 - The t(6;14)(p21;q32) translocation causes dysregulation of cyclin d3 in multiple myeloma

AU - Qi, Ying

AU - Gabrea, Ana

AU - Sawyer, Jeffrey

AU - Shaughnessy, John D.

AU - Barlogie, Bart

AU - Bergsagel, Peter Leif

AU - Michael Kuehl, W.

PY - 2000

Y1 - 2000

N2 - Reciprocal translocations involving the IgH locus (14q32) appear to provide an early transformation event in most multiple myeloma (MM) tumors. These primary translocations are targeted to V/D/J sequences due to errors in VDJ recombination or somatic hypermutation, or to IgH switch regions due to errors in switch recombination. The translocations include a promiscuous array of at least 20 nonrandom chromosomal partners, each including an oncogene that is dysregulated by juxtaposition to potent IgH enhancers. The most frequent partners include: Hql3(cyclin Dl), 4pl6.3 (FGFR3 and MM.SET), and 16q23 (c-maf), which together are present in approximately 50% of MM tumors. Cyclin D3 is expressed at similar levels in 25 MM cell lines, except for one cell line that expresses nearly ten times as much cyclin D3 mRNA and protein as any other cell line. In this MM cell line, FISH analyses confirmed the presence of a t(6; 14)(p21 ;q32) translocation, with close juxtaposition of cyclin D3 and IgH Ea enhancer sequences. The cloned translocation breakpoint junction occurs within a y4 IgH switch region and includes 6p21 sequences that co-localize with cyclin D3 sequences on a BAC clone. In screening a panel of 30 MM tumors, we identified a single tumor with at(6;22)(p21;qll) translocation, with cyclin D3 and CX enhancer sequences juxtaposed on der(6). As a result the IgH and IgX translocations bracket the cyclin D3 gene, similar to results obtained for other genes (c-myc, c-maf) dysregulated by Ig translocations. From conventional cytogenetic and/or SKY analyses of several hundred MM tumors, the t(6;14)(p21;q32) translocation is present in about 2-3% of tumors. Additional FISH analyses of metaphase chromosomes confirm that: 1) cyclin D3 and IgH E

AB - Reciprocal translocations involving the IgH locus (14q32) appear to provide an early transformation event in most multiple myeloma (MM) tumors. These primary translocations are targeted to V/D/J sequences due to errors in VDJ recombination or somatic hypermutation, or to IgH switch regions due to errors in switch recombination. The translocations include a promiscuous array of at least 20 nonrandom chromosomal partners, each including an oncogene that is dysregulated by juxtaposition to potent IgH enhancers. The most frequent partners include: Hql3(cyclin Dl), 4pl6.3 (FGFR3 and MM.SET), and 16q23 (c-maf), which together are present in approximately 50% of MM tumors. Cyclin D3 is expressed at similar levels in 25 MM cell lines, except for one cell line that expresses nearly ten times as much cyclin D3 mRNA and protein as any other cell line. In this MM cell line, FISH analyses confirmed the presence of a t(6; 14)(p21 ;q32) translocation, with close juxtaposition of cyclin D3 and IgH Ea enhancer sequences. The cloned translocation breakpoint junction occurs within a y4 IgH switch region and includes 6p21 sequences that co-localize with cyclin D3 sequences on a BAC clone. In screening a panel of 30 MM tumors, we identified a single tumor with at(6;22)(p21;qll) translocation, with cyclin D3 and CX enhancer sequences juxtaposed on der(6). As a result the IgH and IgX translocations bracket the cyclin D3 gene, similar to results obtained for other genes (c-myc, c-maf) dysregulated by Ig translocations. From conventional cytogenetic and/or SKY analyses of several hundred MM tumors, the t(6;14)(p21;q32) translocation is present in about 2-3% of tumors. Additional FISH analyses of metaphase chromosomes confirm that: 1) cyclin D3 and IgH E

UR - http://www.scopus.com/inward/record.url?scp=33748674230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748674230&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748674230

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART I

ER -